📷 Image: Wikimedia Commons / Bollywood Hungama
Business
Aarti Drugs' Baddi Plant Receives Three FDA Form 483 Observations
✍️ CNBC TV18
🗓 07 Nov 2026, 12:52 PM
👁 8
The US Food and Drug Administration has issued three Form 483 observations against Aarti Drugs' manufacturing unit in Baddi, Himachal Pradesh, citing compliance issues.
Aarti Drugs, a leading Indian pharmaceutical company, has recently received three Form 483 observations from the US Food and Drug Administration (FDA) at its Baddi manufacturing facility.
Form 483 is issued when the FDA identifies potential violations of the Federal Food, Drug, and Cosmetic Act during inspections. The observations point to areas where the company must enhance its processes to meet FDA standards.
The Baddi plant is a critical site for Aarti Drugs, producing a range of pharmaceutical products. The observations could impact the company’s export operations and regulatory compliance status.
Aarti Drugs has stated that it is reviewing the FDA’s findings and will implement corrective actions. The company has not yet indicated any immediate effect on its product supply chain.
Form 483 is issued when the FDA identifies potential violations of the Federal Food, Drug, and Cosmetic Act during inspections. The observations point to areas where the company must enhance its processes to meet FDA standards.
The Baddi plant is a critical site for Aarti Drugs, producing a range of pharmaceutical products. The observations could impact the company’s export operations and regulatory compliance status.
Aarti Drugs has stated that it is reviewing the FDA’s findings and will implement corrective actions. The company has not yet indicated any immediate effect on its product supply chain.